

Stem Cells

The present invention relates to stem cells, in particular to a new type of stem cells that can be 5 isolated from bone marrow and blood.

Stem cells can produce new cells to repair damage to any tissue in the body and therefore have immense potential for all types of regenerative medicine. Stem cells are present in all body tissues and organs but 10 some, like bone marrow and blood, are more accessible than others, like liver and brain. However, stem cells exist in very small numbers in marrow and blood, and need to be extracted then increased in number ("expanded") before they can be used clinically. Currently, many 15 attempts are being made to accomplish the aim of providing stem cells in sufficient numbers to perform tissue-specific stem cell transplantation.

Efforts have focussed on the bone marrow as a source of stem cells. Evidence to date suggests that the bone 20 marrow contains two types of stem cells - haemopoietic stem cells (HSC) responsible for producing blood, and mesenchymal stem cells (MSC) capable of producing cells belonging to a limited range of body tissues. MSC can not be precisely defined or isolated and show a limited 25 capacity to provide multiple cell types. They form osteoblasts, chondroblasts and adipocytes in response to stimulation in culture but there are many cell types, such as hepatocytes, which they cannot form. Prolonged culture of MSC results in the outgrowth of a 30 subpopulation of cells referred to as multipotent adult progenitor cells (MAPC) which to date appear to have the broadest potential for tissue regeneration. However, the fact that prolonged tissue culture and many cell divisions are required before MAPC emerge means, first, 35 that they may have accumulated genetic damage and second, that it is impossible to be certain that they represent normal cellular components of the bone marrow. They may,

in fact, be a tissue culture artefact. These important considerations potentially contra-indicate the clinical use of MAPC. MAPC can form cells with endodermal, ectodermal or mesodermal markers but, significantly, do 5 not produce haemopoietic cells in culture.

Using differentiated cells derived from stem cells to produce their natural protein products has advantages over the use of cells to produce recombinant proteins, particularly because of the capability for appropriate 10 glycosylation and post-translational modification of the protein product.

The present inventors have now identified a new type of stem cell which can be directly isolated from adult bone marrow and blood, e.g. peripheral blood, and have 15 the unique ability to differentiate into ectodermal, mesodermal and endodermal cells. These cells are thus clearly multipotent if not totipotent. Thus the stem cells described herein provide a novel source of cells for tissue transplantation that may be used in an 20 autologous (self-to-self) manner. Further, as is described below, these stem cells do not require prolonged tissue culture.

The stem cells of the present invention are preferably obtained from a sample taken from an adult 25 such as adult bone marrow or peripheral blood from an adult. Thus the cells are preferably adult stem cells. The cells may also be obtained from other samples such as the umbilical cord and the stem cell population of the present invention may thus in one embodiment comprise 30 fetal as well as adult cells. Fetal sources, eg fetal liver or bone marrow, may also be used.

Thus, in one aspect the present invention provides an isolated stem cell population wherein said stem cells are CD34<sup>+</sup>, capable of self regeneration and capable of 35 differentiation into ectodermal, mesodermal and endodermal cells, preferably into haemopoietic cells. Preferably, the stem cells are adult stem cells.

These stem cells are further characterised by their ability to adhere to plastic (e.g. the plastic of standard tissue culture vessels) during culturing. The cells are thus "capable of" adhering to plastic in the 5 culturing methods described herein and without any special further conditions or modifications. Suitable vessels are those manufactured by Corning Incorporated, New York, USA.

The stem cells of the invention may be further 10 characterised by the fact that they do not require feeder layers, i.e. cells (typically inactivated by gamma irradiation which supply important metabolites without further growth or division of their own) which support the growth of the stem cells. Thus, preferably, a feeder 15 layer is not used during culturing of the stem cells.

One primary characterising and particularly advantageous feature of these stem cells is their ability to differentiate into a very wide variety of different cell types including ectodermal, mesodermal and 20 endodermal cells. Thus, these stem cells of the invention can differentiate into cell types which are developmentally derived from the three germ layers of the embryo; ectoderm, mesoderm and endoderm; for example haemopoietic and muscle cells which are derived from the 25 mesoderm; nerve or epithelial cells from the ectoderm; and glandular epithelium or hepatocytes from the endoderm.

The cell population is 'isolated' in that it is substantially free of other cell types. Preferably, it is substantially free of cell types which express CD33, 30 CD38, HLA/DR, CD19 and CD3. 'Substantially free' should be interpreted to be consistent with the empirical data presented in the examples. Also, the population is substantially free of cells dedicated to a particular lineage and/or cells carrying markers associated 35 therewith. Preferably the population has less than 20%, more preferably less than 10%, e.g. less than 5% of lineage committed cells. It may assist in the isolation

of the present stem cell population to combine both negative selection (removal of cells) and positive selection (isolation of cells), in both cases antibody binding may be used. 'Isolated' cells include those 5 which have been directly isolated from a sample as well as cells cultured or derived from such a sample.

Stem cells are thought to be manufactured in the adult bone marrow but are also found in the blood. The present stem cells may be collected from either of these 10 sources according to standard sampling techniques. Blood samples are preferably obtained following stem cell mobilisation with G-CSF to increase the numbers of stem cells in the circulation. For example, 5 µg/kg body weight/day may be administered subcutaneously for 5 days. 15 It is also possible to obtain direct bone marrow samples, e.g. through aspiration.

Bone marrow cells may be obtained from a source of bone marrow, e.g., iliac crests, tibiae, femora, spine, or other bone cavities. Conveniently bone marrow may be 20 aspirated from the bone in accordance with conventional techniques. Other sources of the stem cells include blood, including adult peripheral blood and umbilical cord blood.

The cells are preferably of mammalian origin, i.e. 25 have been isolated from a mammalian sample or are derived from cells isolated from such a sample. Particularly preferred mammals are humans and mice. Further preferred mammals include cows, horses and companion animals.

Various techniques may be employed to separate the 30 cells by initially removing cells of dedicated lineage. Monoclonal antibodies are particularly useful for identifying markers (surface membrane proteins) associated with particular cell lineages and/or stages of differentiation. The antibodies may be attached to a 35 solid support to allow for crude separation. The separation techniques employed should maximize the retention of viability of the fraction to be collected.

- 5 -

For "relatively crude" separations, that is, separations where up to 10%, usually not more than about 5%, preferably not more than about 1%, of the total cells present do not have the marker but may remain with the 5 cell population to be retained, since various techniques of different efficacy may be employed. The particular technique employed will depend upon efficiency of separation, cytotoxicity of the methodology, ease and speed of performance, and necessity for sophisticated 10 equipment and/or technical skill.

Procedures for separation may include magnetic separation, using antibody-coated magnetic beads, affinity chromatography, cytotoxic agents joined to a monoclonal antibody or used in conjunction with a 15 monoclonal antibody, e.g., complement and cytotoxins, and "panning" with antibody attached to a solid matrix, e.g., plate, or other convenient technique. Techniques providing accurate separation include fluorescence activated cell sorters, which can have varying degrees of 20 sophistication, e.g., a plurality of color channels, low angle and obtuse light scattering detecting channels, impedance channels, etc.

Conveniently, the antibodies may be conjugated with markers, such as magnetic beads, which allow for direct 25 separation, biotin, which can be removed with avidin or streptavidin bound to a support, fluorochromes, which can be used with a fluorescence activated cell sorter, or the like, to allow for ease of separation of the particular cell type. Any technique may be employed which is not 30 unduly detrimental to the viability of the remaining cells.

Preferably the mononuclear fraction of the blood or bone marrow sample is separated using a Lymphoprep™ (Axis Shield) density gradient. CD34<sup>+</sup> cells can be separated 35 from the mononuclear fraction using MiniMACS (Miltenyi Biotec) technology.

The stem cells of the present invention can be further characterised by the methods used to obtain them, thus the cells are obtainable by a combined affinity purification and selection by adherence method. More particularly, the cells can be labelled with CD34 monoclonal antibody (MAb) and then with (para)magnetic beads which themselves bind to the CD34 MAb. Alternatively, beads which are themselves labelled with the CD34 MAb may be used which bind to the cells. The labelled or bound cells can then be applied to a column and held in place by a magnet; unlabelled cells will be eluted and labelled cells released by removing the magnet (or by removing the column from the magnet).

The thus released CD34<sup>+</sup> cells can then be incubated at a suitable temperature of e.g. between 35-38° C, preferably 37° C in tissue culture plastic vessels for at least 2 hours, preferably at least 3 hours e.g. 3-5 hours, with non-adherent cells removed by washing with HBSS (Hanks balanced salt solution). The adherent CD34<sup>+</sup> cells are the stem cells of the present invention and comprise less than 1% of the total CD34<sup>+</sup> population. They are preferably a substantially homogenous population, generally uncontaminated by other stem cell subpopulations. Typically less than 30%, preferably less than 20% more preferably less than 5%, most preferably less than 3% of the cells collected are other than the stem cells of the present invention. However, the Examples show that all individual markers may not be found on every cell in the isolated population and the term "homogenous population" should be interpreted with this in mind. The stem cell population of the invention is preferably homogeneous with respect to CD34 expression, adherence to tissue-culture grade plastic and small lymphocyte-like morphology. 'Adherent' cells are defined as those which are able to resist vigorous washing three times without detaching from a solid support (in particular tissue-culture grade plastic or

glass). The advantageous properties of the adherent subset of CD34<sup>+</sup> cells are surprising as the adherent cells would usually be discarded when preparing cells for culture.

5 The stem cells of the invention are capable of self-regeneration, i.e., in accordance with standard definitions of stem cells, stem cells are capable of division to form further stem cells, as well as differentiation to a wide variety of different cell  
10 types.

The stem cells of the invention are further characterised as CD34<sup>+</sup>, i.e. expressing the antigen CD34, a glycoprotein marker found, but not exclusively so, on stem cells, in particular the stem cells manufactured in  
15 the bone marrow (HSC and MSC). The stem cell population of the present invention may also be enriched for cells expressing the Thy-1 marker, i.e. comprise a significant proportion of cells which are Thy-1<sup>+</sup>. The stem cell population may thus be enriched for Thy-1 relative to the  
20 starting cell population (the sample). Example 5 indicates that on average 28.1%, but up to 90% of cells are Thy-1<sup>+</sup>.

More particularly, the cells may be characterised as CD34<sup>+</sup>, CD38<sup>-</sup>, CD33<sup>-</sup> and HLA-DR<sup>-</sup>. Preferably the cell  
25 population is also enriched for AC133<sup>+</sup>, Thy-1<sup>+</sup> and/or c-met<sup>+</sup>, more preferably cells are predominantly AC133<sup>+</sup>, Thy-1<sup>+</sup> and/or c-met<sup>+</sup>.

The stem cells are lymphocyte-like in that they are round mononuclear cells and rather small with a high  
30 nucleus: cytoplasm ratio. Such a morphology is associated with primitive stem cells.

They are characterised by an ability to produce differentiated cells in less than 16, e.g. 12-14 days in culture. Preferably differentiation is observed in less  
35 than 14 days, e.g. less than 10 days, more preferably in less than 7 days, even 4-5 days.

- 8 -

The stem cells of the invention can be further characterised as obtainable by:

- 5 (i) subjecting haemopoietic tissue (i.e. blood or a bone marrow sample) to density gradient separation;
- (ii) exposing low density cells to an affinity ligand for CD34 (preferably attached to paramagnetic beads);
- 10 (iii) recovering cells attached to said CD34 ligand;
- (iv) exposing the CD34<sup>+</sup> subpopulation to tissue culture grade plastic; and
- 15 (v) recovering CD34<sup>+</sup> cells adherent to the plastic.

A sample of the stem cells of the present invention was deposited with European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, SP4 0JG, UK on 24 September 2004 under accession number 04092401. The deposit was made by the inventor and the cell line was given the name "Stem Cell Omnicyte".

The stem cells of the invention may be from any animal, e.g. laboratory, livestock or companion animal; preferably primate and most preferably from humans.

In a further embodiment the present invention provides a culture comprising:

- 25 (i) an isolated adult stem cell population wherein said stem cells are CD34<sup>+</sup>, capable of self regeneration and capable of differentiation into ectodermal, mesodermal and endodermal cells; and
- (ii) a medium capable of supporting the growth of said stem cells.

Preferably, the present invention provides a culture comprising

- 35 (i) a(n isolated) stem cell population wherein said stem cells are CD34<sup>+</sup>, capable of self regeneration and capable of differentiation into ectodermal,

mesodermal and endodermal cells and capable of adhering to tissue-culture grade plastic; and

- (ii) a medium capable of supporting the growth of said stem cells.

5

Once stem cells have been isolated, they may be propagated by growing in conditioned medium from stromal cells, such as stromal cells that can be obtained from bone marrow, fetal thymus or fetal liver, and are shown 10 to provide for the secretion of growth factors associated with stem cell maintenance, coculturing with such stromal cells, or in medium comprising maintenance factors supporting the proliferation of stem cells, where the stromal cells may be autologous, allogeneic or 15 xenogeneic. Before using in the coculture, the mixed stromal cell preparations may be freed of haemopoietic cells employing appropriate monoclonal antibodies for removal of the undesired cells, e.g., with antibody-toxin conjugates, antibody and complement, etc. Alternatively, 20 cloned stromal cell lines may be used where the stromal lines may be allogeneic or xenogeneic. Thus, reference above to "medium" includes cells such as stromal cells.

The stem cells of the invention and differentiated cells derived therefrom can survive cryopreservation in 25 liquid nitrogen.

In a further aspect, the invention provides a method of isolating an adult stem cell population wherein said stem cells are CD34<sup>+</sup>, capable of self regeneration and capable of differentiation into ectodermal, mesodermal 30 and endodermal cells, which method comprises taking a sample of blood or bone marrow from a subject and extracting said cell population therefrom. Preferably, the invention provides a method of isolating a stem cell population wherein said stem cells are CD34<sup>+</sup>, capable of self regeneration and capable of differentiation into ectodermal, mesodermal and endodermal cells and capable 35 of adhering to tissue-culture grade plastic which method

- 10 -

comprises taking a sample of blood or bone marrow from a subject and extracting said cell population therefrom. Preferred extraction steps are discussed above and in the case of blood sampling there will typically be a first 5 step of stem cell mobilisation which is preferably performed by administering G-CSF to the subject.

Adhesion to tissue culture plastic is a property of several cell types including marrow mesenchymal stem cells, monocytes and macrophages, but has not previously 10 been used to characterise or isolate a subpopulation of CD34-positive cells. Adherence to tissue culture plastic has been found to be a simple, reproducible and practicable means of selecting primitive stem cells without resort to multiple antibody labelling procedures 15 or other manipulation. The CD34+ cells of the present invention are also capable of adhering to glass, and glass or other suitable solid supports may thus be used instead of the tissue-culture grade plastic in the methods of the present invention.

20 The stem cells of the present invention have utility in research contexts, for example in detecting and evaluating growth factors relevant to stem-cell regeneration. The stem cells may also be of direct utility in the treatment of genetic diseases through gene 25 modification or replacement in autologous stem cells. In particular the cells may be used in the treatment of diseases associated with haemopoietic cells, such as  $\beta$ -thalassemia and sickle cell anemia, where a wild-type gene is introduced into the stem cells. Thus in a 30 further aspect the invention provides an isolated adult stem cell population wherein said stem cells are CD34+, capable of self regeneration and capable of differentiation into both haemopoietic and mesenchymal cells which further incorporate a therapeutic gene, for 35 use in therapy.

Preferably, the invention provides an isolated stem cell population wherein said stem cells are CD34+, capable

- 11 -

of adhering to tissue-culture grade plastic and capable of self regeneration and capable of differentiation into both haemopoietic and mesenchymal cells which further incorporate a therapeutic gene, for use in therapy.

5 Equally, the invention provides a method of gene therapy comprising administering to a patient in need thereof a population of stem cells wherein said stem cells are CD34<sup>+</sup>, capable of self-regeneration and capable of differentiation into ectodermal, mesodermal and

10 endodermal cells and incorporate a therapeutic gene. Preferably, the invention provides a method of gene therapy comprising administering to a patient in need thereof a population of stem cells wherein said stem cells are CD34<sup>+</sup>, capable of adhering to tissue-culture

15 grade plastic and capable of self-regeneration and capable of differentiation into ectodermal, mesodermal and endodermal cells and incorporate a therapeutic gene.

Suitable therapeutic genes will include a wild-type version of a gene which is defective in the patient or a drug resistance gene.

Without additional therapeutic genes the stem cells still have therapeutic utility, e.g. in regenerating the haematopoietic system of a patient deficient in stem cells.

25 Further utilities of great interest relate to the generation of different differentiated cell types from the stem cells of the invention. As shown in the Figures hereto, it has been possible to generate in advantageously short timescales mesenchymal,

30 haemopoietic, endothelial, epithelial, tube-forming and dendrite-forming cells. The preparation of haemopoietic and mesenchymal cells being particularly preferred. Cells have been observed after less than 14 days with the appearance of liver, nerve, mesenchymal, endothelial,

35 epithelial and haemopoietic cells.

The stem cells are cultured with a cocktail of different cytokines, depending on the desired cell type.

The cocktail will typically comprise G-CSF, GM-CSF, IL-3 and stem cell factor, with HGF and FGF being added to stimulate differentiation of hepatocytes; nicotinamide and LY294002 to stimulate differentiation to pancreatic 5 cells and FGF and dibutyryl cyclic AMP to encourage production of nerve cells. Other growth factors are known to the skilled man to be important in the differentiation of other cell types such as bone, cartilage, skeletal and cardiac muscle, kidney, lung, 10 nerve, skin and endocrine tissue. Preferred cell types which are produced in this way are liver, pancreatic, haemopoietic, neuronal and oligodendrocytic cells.

Thus, in a further aspect, the invention provides a method of producing a target cell type which comprises 15 culturing the stem cells of the invention with a plurality of growth factors. As described in the Examples and shown in the Figures, successful differentiation may be shown by visual inspection, flow cytometry, reverse transcriptase polymerase chain 20 reaction (RT-PCR) or immunophenotyping. Cells expressing albumin,  $\alpha$ -fetoprotein,  $\alpha 1$ -antitrypsin and hepatocyte growth factor receptor (HGF receptor - c-met) (properties of hepatocytes), vimentin (skeletal muscle and neuronal cells) and smooth muscle actin (muscle cells), in 25 addition to CD34 have, for example, been confirmed.

The differentiated cells will preferably have characteristics, e.g. morphology, and functions of their naturally occurring counterparts. The differentiated cells may, however, be distinguished from naturally 30 occurring and isolated cells by their homogeneity, in this situation homogeneity is with reference to the position of the cells in the normal cell cycle. These differentiated cell populations of the invention will be substantially homogeneous, i.e. all members will largely 35 be at the same point in the cell cycle; in contrast naturally occurring cell populations will be heterologous in this respect.

The differentiated cells can then be transplanted into a patient in need thereof. Of particular benefit is the potential to generate differentiated cells for cell or tissue transplantation that are derived from the 5 patient's own stem cells. Such techniques are known in the art and use different routes of administration according to the particular target tissue. The liver for example is able to regenerate itself following introduction of a population of healthy liver cells, 10 where the liver has been damaged, e.g. as a result of Hepatitis infection or alcohol abuse. Immune suppression may be treated by administration of lymphocytes, muscle wasting by the introduction of skeletal muscle cells, diabetes through transplanting pancreatic cells and so 15 on.

The cells may be administered in a localised manner, e.g. injected directly into a target organ such as the liver. Alternatively, the cells may be administered at a site remote from the target site, e.g. by intravenous 20 delivery. Tissue targeting may be achieved by forming a complex between the generated cell types and a targeting ligand, such as monoclonal antibodies, cell adhesion molecules and their ligands, cytokine, chemokine and toll-like receptors and their ligands. Such 'complexes' 25 include cells which express the targeting ligand on their cell surface.

The stem cells of the invention may be used directly in therapeutic methods, including methods of regeneration and repair, differentiation of the cells may occur *in* 30 *vivo*. With stem cells and differentiated cells damaged organs may be repaired and/or there may be organ regeneration, also in circumstances where the organ has not been 'damaged' as such but has not developed in the normal way. 'Regeneration' should thus be interpreted 35 broadly to include all methods of organ growth or improvement.

In one preferred embodiment the transplanted cells are adapted to be tracked *in vivo*, i.e. they incorporate a labelling moiety which means the location of the cells in the body can be identified. Conveniently the cells 5 will incorporate iron compounds e.g. iron oxide, and then MRI can be used to confirm the location of the transplanted cells, in particular to confirm whether they have reached their target tissue. As described in Example 4, the MR agent Resovist® is a suitable iron 10 containing compound which can be taken up by the cells on incubation therewith.

Thus, according to further aspects, the invention provides differentiated cell populations prepared according to the method defined above and such cells for 15 use in therapy, as well as methods of medical treatment which comprise administration of these differentiated cell populations to a patient. In particular, the invention comprises a method for the transplantation of a population of differentiated cells, the method 20 comprising:

- (i) culturing a population of the stem cells of the present invention with a plurality of growth factors so as to cause differentiation thereof; and
- 25 (ii) transplanting said differentiated cells into a patient.

Preferably the patient is human and also preferably, the stem cells which are cultured to produce the differentiated cells are from the patient.

30 The short time required from taking a sample from a patient and growing up differentiated cells for administration is a particular benefit provided by the present invention.

The stem cells of the invention and differentiated 35 cells derived therefrom may also be used in the *in vitro* production of proteins of interest. Thus in a further aspect the invention provides an *in vitro* method of

protein production which comprises culturing the stem cells of the invention or a differentiated cell line derived therefrom and then harvesting the cells and recovering one or more of the proteins expressed by said cells.

5 Animal cells have become the predominant protein expression system for *in vitro* production of target proteins, particularly therapeutic agents, because of their ability to perform post-translational modification 10 (e.g. glycosylation) of proteins. The stem cells of the invention and their differentiated progeny can be used in the production of most if not all proteins of therapeutic interest, such as erythropoietin, growth factors, protein hormones such as insulin etc. or synthetic proteins. The 15 cells may be genetically modified in order to provide or enhance production of a particular target protein. However it is a particularly desirable feature of the cell types enabled by the present invention that differentiation to an appropriate cell type (e.g. 20 parenchymal cells) can be performed such that the cells naturally produce the target protein without the need for genetic engineering.

The above described uses of the cells of the invention (stem and differentiated) are also applicable 25 to non-protein products such as steroids, in both cases, suitable culturing and harvesting techniques are known to the skilled man.

The stem cells of the invention have the necessary cellular machinery to propagate vectors such as 30 adenovirus, retrovirus, adeno-associated virus etc.; this is an essential step for current good manufacturing practice (cGMP) preparation of such vectors. Thus, in a further aspect, the present invention provides the use of the stem cells of the invention as defined and described 35 herein in vector, particularly viral vector, production. Alternatively viewed, the invention provides a method of vector production wherein the vector of interest is

- 16 -

propagated in a stem cell of the invention as defined and described herein. The vector (a transmissible agent) is typically a viral vector such as an adenovirus, retrovirus or adeno-associated virus.

5 The invention will be further described in the following non-limiting Examples and with reference to the Figures in which:

10 Figures 1-10 are photographs showing the stem cells of the invention and their differentiation over time into mesenchymal cells (Fig. 3, 5 and 6), haemopoietic cells (Fig. 4), epithelioid cells (Figs. 7 and 8), tube-forming cells (Fig. 9) and dendrite-forming cells (Fig. 10).

15 Figure 11 is a photograph showing how CD34<sup>+</sup> cells were able to take up Resovist® (Schering AG) according to the protocol described in Example 4. According to this figure the individual spots represent the following:

1. 10<sup>6</sup> cells, 0.25 mmol Resovist, overnight incubation
2. 10<sup>6</sup> cells, 0.25 mmol Resovist + beads, overnight  
20 incubation
3. 10<sup>6</sup> cells, beads, overnight incubation
4. 10<sup>6</sup> cells, negative control (no staining)
5. 5x10<sup>5</sup> cells, negative control (no staining)
6. 5x10<sup>5</sup> cells, 0.25 mmol Resovist, overnight incubation
- 25 7. 5x10<sup>5</sup> cells, 0.25 mmol Resovist + beads, overnight incubation
8. 5x10<sup>5</sup> cells, beads, overnight incubation
9. 10<sup>6</sup> cells, 0.25 mmol Resovist, 2h incubation
10. 10<sup>6</sup> cells, 0.25 mmol Resovist + beads, 2h incubation
- 30 11. 10<sup>6</sup> cells, beads, 2h incubation
12. 5x10<sup>5</sup> cells, 0.25 mmol Resovist, 2h  
incubation
13. 5x10<sup>5</sup> cells, 0.25 mmol Resovist + beads, 2h  
incubation
14. 5x10<sup>5</sup> cells, beads, 2h incubation
- 35 15. beads only, no cells.

- 17 -

Figure 12 are photographs showing the differentiation of stem cells into liver cells, as evidenced by the presence of the liver cell markers albumin and alpha fetoprotein.

5 Figure 13 is a graph showing that adding hepatocyte growth factor (HGF) and epidermal growth factor (EGF) to basic cytokines (GM-mix) (GM-mix/basic cytokines are combination of G-CSF, GM-CSF, IL-3 and stem cell factor) on day 7 of culture incubation has a greater impact on 10 cell number than adding them on day 0 or day 3.

Figure 14 is a graph showing the actual and cumulative cell numbers in cultures maintained in basic cytokines for 60 days.

15 Figure 15 is an autoradiograph of a gel demonstrating telomerase activity of cells after 7 days of culture.

20 Figure 16 is photographs of microscope slide preparations developed by immunoperoxidase immunocytochemistry showing absence of human cytokeratin 18 from livers of control mice but cytokeratin 18 positivity in livers from transplanted mice.

25 Figure 17 is photographs of microscope slide preparations developed by immunoperoxidase immunocytochemistry showing absence of human albumin from livers of control mice but albumin positivity in livers from transplanted mice.

Figure 18 is a photograph of a three colour immunofluorescent image showing dual staining of cytokeratin 18 and albumin.

30 Figure 19 is photographs of liver sections from control and transplanted mice showing absence and presence, respectively, of cells stained with an antibody against human nuclei.

35 Figure 20 is a photograph showing fluorescent in situ hybridisation analysis of human chromosomes in liver from transplanted mice.

- 18 -

Figure 21 is a graph showing the effects of cryopreserving freshly isolated ASC34, in different serum concentrations, on their subsequent growth in culture

ExamplesSection A5 Example 1. Cell extraction

Haematopoietic cells were obtained from bone marrow or mobilised blood from normal individuals for transplantation purposes. The mononuclear fraction was 10 separated from the whole using a Lymphoprep™ density gradient. CD34<sup>+</sup> cells were separated from mononuclear fraction using Minimacs technology. Cells were first labelled with CD34 monoclonal antibody and then with paramagnetic beads. Labelled cells were loaded onto a 15 column held on a magnet, unlabelled cells were eluted and labelled cells released by removing the column from the magnet. The CD34<sup>+</sup> cells were incubated at 37°C in tissue culture plastic vessels for at least 2h. Non adherent cells were removed by washing with HBSS.

20

Example 2. Cell culture

Cells (2 x 10<sup>5</sup>/ml) were incubated in Methylcellulose medium containing serum, 100ng/ml granulocyte colony 25 stimulating factor (G-CSF), 5ng/ml interleukin-3 (IL-3) 20ng/ml stem cell factor (SCF) and 1ng/ml granulocyte macrophage colony stimulation factor (GM-CSF). This cytokine combination may also be referred to as ``basic cytokines or ``GM-mix''. This resulted in heterogeneous 30 populations of cells, which subsequently can be characterised. Selected individual populations were then targeted for differentiation using tailored cytokine cocktails.

35 Example 3. Flow cytometry and immunocytochemistry

- 20 -

Flow cytometry. The adherent population that had developed in the cultures was removed by scraping the dish. Cells were fixed in 4% paraformaldehyde and permeabilised. Cells were labelled with monoclonal antibodies conjugated with FITC and analysed using Becton Dickinson flow cytometer.

Immunocytochemistry. The adherent population that had developed in the cultures was removed by scraping the dish. Cells were cytospun onto glass slides and fixed by methanol. Cells were labelled with monoclonal antibodies and visualised using the APAAP (alkaline phosphatase anti-alkaline phosphatase) reaction.

15 Results of flow cytometry and immunocytochemistry are shown in Table 1 below.

Table 1.

Antigen	Flow cytometry	Immunocytochemistry
Albumin	9.2%*	Large cells +ve**
Alpha feto protein	12.3%	Large cells +ve
Alpha 1 antitrypsin	20.1%	N/A
cMET (HGF receptor)	34.9%	+ve
Smooth muscle actin	61.2%	Large cells +ve
GFAP(astrocytes)	57.4%	- ve
cKIT	22.1%	- ve
Vimentin	6.3%	Large cells +ve
hTERT	20.1%	- ve

20

\* Denotes % of positive cells in the population

\*\* Denotes that the large cells in the population were positive and the small cells were negative.

25 Albumin, alpha feto protein, alpha 1 antitrypsin and c-MET (HGF receptor) are liver cell markers; GFAP

- 21 -

(astrocytes) is a brain cell marker; and smooth muscle actin is a marker for mesenchyme cells.

Figure 12 shows cells exhibiting liver cell markers after 5 culturing for 12 days.

Example 4. Incorporation of iron oxide into cells and labelling cells with paramagnetic beads

10 CD34<sup>+</sup> ( $10^6$  and  $5 \times 10^5$ ) cells were incubated with 0.25 mmol Resovist® (the brand name of Ferriixan, carboxy-dextran coated iron oxide nanoparticles available from Schering AG) for 2 and 24 hours at 37°C and analysed by MRI. In both cases, positive signal was obtained by 15 MRI suggesting possible use of Resovist in detecting CD34<sup>+</sup> cells *in vivo*. The results of Figure 11 indicate that the particles can be taken up by the cells and therefore used in tracking the CD34<sup>+</sup> cells or their differentiated progeny as they move around the body or locate in target 20 tissues.

The *in vitro* toxicity of Resovist was also tested by Trypan blue exclusion assay and proved to be non-significant (<4%).

25 The results of this experiment are shown in Fig. 11.

Section B (Additional examples)

Example 5: Sources of ASC 34

30 Bone marrow (BM) obtained from healthy donors by aspiration, mobilised peripheral blood (PB) obtained by leukapheresis from healthy donors who had been given a course of granulocyte colony-stimulating factor (G-CSF) and umbilical cord blood (UCB) obtained from normal full- 35 term deliveries are commonly used sources of ASC 34. Informed consent and Research Ethics Committee approval is required in all cases.

As well as being found in adult haemopoietic tissue and cord blood, ASC-34 activity has been detected in adult bone marrow, full-term umbilical cord blood, fetal liver (gestational age 11.6-13.8 weeks) and fetal bone marrow 5 (12.7-15.4 weeks). These cells are distinct from embryonic stem cells because an embryo is considered to become a foetus at 8 weeks post fertilisation.

10 Example 6: Purification of a homogeneous population of adherent CD34-positive human stem cells (ASC34)

Initial purification of stem cells to homogeneity is desirable for the subsequent investigation of their potential for self-renewal, differentiation and in vivo 15 engraftment. Such a population is obtained by sequential density gradient separation, immunomagnetic bead selection and differential adherence, and is homogeneous with respect to CD34 expression, adherence to tissue-culture grade plastic or glass and small lymphocyte-like 20 morphology.

The mononuclear cell (MNC) fraction was separated from the whole sample by density gradient centrifugation through Lymphoprep and the CD34-positive cell fraction 25 was then separated from the MNC using MiniMACS technology (Miltenyi Biotech). For this, cells were first labelled with anti-CD34 monoclonal antibody and then with paramagnetic microbeads. The labelled cells were loaded onto a column held on a magnet, the unlabelled cells were 30 eluted and then the labelled cells were released by removing the column from the magnet. The purified (>98%) CD34-positive cells were diluted to  $2 \times 10^5$ /ml in alpha medium supplemented with 15% serum.

35 Adherent CD34-positive stem cells (ASC34) were obtained by incubating the CD34-positive cell suspension in tissue culture plastic vessels for at least 2 hours at 37° C.

The non-adherent CD34-positive cells were removed by washing the tissue culture vessels in Hanks' Balanced Salt Solution (HBSS).

5 Adherent CD34-positive stem cells comprise ~1% of the total CD34-positive cell population irrespective of the haemopoietic tissue (BM, PB, UCB) used to initiate the cultures. Undifferentiated CD34+ adherent stem cells (ASC34) exhibit a homogeneous small lymphocyte-like

10 morphology with a high nuclear:cytoplasmic ratio. At culture initiation they are widely spaced as single cells on the tissue culture surface. The initiating cells are, by definition, CD34-positive. Antibody-depletion with anti-Thy-1 monoclonal antibody removed virtually all the

15 activity of the adherent CD34+ cells as measured using the production of myeloid colony-forming cells as a readout; according to immunocytochemistry results using cells isolated from 6 independent samples, 28.1% on average, but up to 90% expressed Thy-1. They also

20 express AC133 and c-met localised in the nucleus but not CD3 or CD19. They do not express CD33, CD38 or HLA-DR. They are non-cycling cells that are resistant to treatment with the cell cycle active drug, 5-fluorouracil.

25

Table 2 demonstrates that the ASC34 are significantly more homogeneous than nonadherent CD34-positive cells, with respect to expression of CD33, CD38 and HLA-DR.

30 **Table 2: Percent antigen negative CD34-positive cells in adherent and non-adherent fractions**

Antigen	Adherent CD34+	Non-adherent CD34+	P value **
CD38 (n=4)	87.6±3.1*	17.4±15.8	0.008
CD33 (n=4)	87.5±4.9	58.8±17.2	0.02
HLA-DR (n=4)	71.4±8.9	43.3±16.9	0.03

\*mean  $\pm$  sem (standard error of the mean); \*\* Mann-Whitney U test comparing adherent and non-adherent CD34+ cells; n=number of samples tested.

5

Example 7: Use of adherence to tissue culture plastic as a selectable marker

Adhesion to tissue culture plastic is a property of 10 several cell types including marrow mesenchymal stem cells, monocytes and macrophages, but has not previously been used to characterise a subpopulation of CD34-positive cells. Adherence to tissue culture plastic has been found to be a simple, reproducible and practicable 15 means of selecting primitive stem cells without resort to multiple antibody labelling procedures or other manipulation. Another advantage is that the cells utilise the plastic as their initial growth substrate and do not require transfer to a separate culture environment 20 after purification.

CD34-positive cells suspended in culture medium are introduced into tissue culture plastic vessels at a concentration of  $5 \times 10^5$  cells per ml. The vessels are 25 incubated at 37°C in humidified 5% CO<sub>2</sub> in air. Non-adherent CD34-positive cells, comprising 99% of the total CD34-positive population, are removed by thorough washing with culture medium. ASC34 bind readily to glass but not to non-tissue culture grade plastics.

30

ASC34 can be retrieved for further study or manipulation by mechanically removing them from the tissue culture plastic using a cell scraper. Trypsin and accutase are ineffective.

35

Example 8: Use of mobilised blood as a source of adherent CD34-positive human stem cells (ASC34)

The number of cells available to start a culture is one limiting factor in the progress of tissue regeneration from cultured stem cells. Bone marrow and umbilical cord 5 blood are favoured sources. However, PBPC (Peripheral Blood Progenitor Cell) harvests yield many more cells to start a culture thus reducing the degree of amplification and time required to generate a clinically useful product.

10 Donors (autologous or allogeneic) are treated with a one-week course of G-CSF at 5mg/kg administered subcutaneously. Cells are harvested by leukapheresis using a programmed apheresis machine. Typical yields of 15 cells range from  $5-10 \times 10^{10}$ , most of which are mononuclear cells and ~1% ( $5-10 \times 10^8$ ) are CD34+. The CD34-positive cells are separated using a CliniMacs system (scaled up version of the MiniMacs). By direct observation, the ASC34 are ~1% of the CD34-positive population ( $5-10 \times 10^6$ ). 20 This estimate has been confirmed by limiting dilution analysis of ASC34 activity using haemopoietic colony-forming cell assays as the readout. Thus, a 3-4 log expansion which is achievable over a period of 1-2 weeks, would yield  $5-100 \times 10^9$  cells for clinical applications.

25

Example 9: Culture of ASC34

Phase 1 conditions: The first phase of the culture consists of expanding the adherent cells. The ASC34 are 30 overlaid with methylcellulose containing serum (Methocult H4230; Metachem Diagnostics, Northampton, UK) and a basic cocktail of cytokines (100 ng/ml G-CSF (Chugai Pharma, London, UK) 1 ng/ml GM-CSF, 5ng/ml IL-3, 20 ng/ml SCF (all from First Link, West Midlands, UK)). The cultures are 35 incubated at 37°C in 5% humidified CO<sub>2</sub> in air. The ASC34 divide and self-renew to form colonies of adherent stem cells and then adherent cells that exhibit morphologies

- 26 -

characteristic of mesenchymal, epithelial, vascular and neural cell types. A 40-fold increase in adherent cell number is achieved in the first week of culture. In addition, non-adherent cells are released into the 5 methylcellulose where large colonies of haemopoietic cells (leukocytes) are found.

Omission of methyl cellulose from the culture milieu reduced cell production by 60%. Increasing CD34+ cell 10 numbers seeded beyond a routine  $5 \times 10^5$ /ml did not lead to a commensurate improvement in cell production. Cell numbers were not improved by the addition of 4mM lithium chloride.

15 Phase 2 conditions: In phase 2, cells are transferred to liquid culture conditions with the addition of further cytokines to induce selective cell differentiation as required. Suitable cytokines for differently directed differentiations are listed below.

20

Table 3: Suitable conditions for directed differentiation

Tissues	Examples of additives
Nerve	DMSO; butylated hydroxyanisole; isobutyl methylxanthine; b-FGF; FGF-8
Pancreas	bFGF; EGF; activin A; betacellin; HGF; nicotinamide
Skeletal muscle	EGF; PDGF; 5-azacytidine
Heart	Norepinephrine; forskolin; retinoic acid
Liver	EGF; HGF; FGF-4
Bone	BMP-4
Cartilage	TGF-beta; dexamethosone; BMP-6

- 27 -

As can be seen in Figure 13, some cytokines were more effective when they were added on day 7 of culture than when they were added on day 0 or day 3. Table 4 shows the effects of different cytokines and combinations on 5 total cell number in 2 week-old cultures.

**Table 4: Effects of different cytokines and cytokine combinations on cell yield\*.**

10

Cytokine(s) added	Day 0	Day 7
aFGF	2.5	0.98
bFGF	1.2	1.0
FGF4	1.0	0.99
IGF	1.75	0.62
VEGF	1.0	1.01
HGF	1.4	0.8
bFGF + IGF	1.38	1.18
VEGF + IGF	0.87	0.71
HGF + FGF4	1.2	-
HGF + VEGF	1.14	1.14
HGF + EGF	1.0	1.8
HGF + $\beta$ cellulin	-	1.0
HGF+EGF+ $\beta$ cellulin+activin A	-	3.5
KGF + nicotinamide + glucose	-	0.83

15 \* cell yield relative to GM mix only ie ratio between cell yield in presence of added cytokines:cell yield in presence of GM-mix alone

The data show that additional cytokines had no major effects on cell number overall. More importantly,

- 28 -

combinations designed to induce differentiation (HGF+EGF+  $\beta$  cellulin+activin A/ KGF + nicotinamide + glucose) did not reduce the cell yield.

Cultures can be maintained in phase 2 conditions for 60 days (Figure 14)

5 Example 10: Telomerase activity

Telomerase activity was measured using the TRAP assay. Cells were transferred into 1x CHAPS buffer and the resulting lysate assayed for protein concentration using a DC assay (Bio-Rad), normalised to 77ng/μl and diluted 10 1:10, 1:40 and 1:160 with CHAPS buffer. Lysates were analysed using the TRAPeze telomerase detection kit (Intergen). The TS primer was labelled at 37°C for 20 min and heat denatured at 85°C for 5 min. The PCR was then run for 28 cycles with an annealing temperature of 59°C. The 15 resulting TRAP products were diluted in TRAP loading dye and run on a 12.5% acrylamide-0.5 x TBE gel, dried and exposed to X-ray film.

20 At the initiation of the culture the cells did not express telomerase activity as assessed by the TRAP assay, which is consistent with the quiescent nature of the cells at isolation. Significant telomerase activity is evident in cells from 7-day old cultures (Figure 15) which is consistent with cell proliferation at that 25 stage.

Example 11: Polymerase chain reaction

30 Lysates were prepared from ASC34 (day 0) and from ASC34-derived cells after 7 and 14 days of culture in basic cytokines or with the addition of HGF or EGF as indicated in the key. In further experiments, cells were analysed for up to 35 days in culture. Separate lysates were prepared from the adherent and non-adherent cell 35 fractions of the cultured cells. Gene expression was analysed by PCR.

- 30 -

Gene expression by ASC 34 at day 0

Self-renewal and pluripotency markers.

5 Rex-1 redox-sensing transcriptional  
repressor

Oct 4 octamer-binding transcription  
factor-4

10 Nanog homeodomain protein promoting ES cell  
self-renewal

Haemopoietic cell markers

15 CD34 haemopoietic stem cell marker

CD133 cholesterol-binding protein prominin 1.  
Lipid raft marker

VWF platelet-endothelial adhesion molecule

TAL-1 von Willibrand factor. Coagulation

20 CXCR4 T cell acute leukaemia-1. Basic helix-  
loop-helix protein

Angiopoietin 1 Ligand for Tie 2. Maintains  
haemopoietic stem cell quiescence

Tie 2 Receptor for angiopoietin-1. Maintains  
haemopoietic stem cell quiescence.

25

Skeletal muscle markers

30 TNNT1 skeletal slow troponin 1

Desmin major intermediate filament protein  
of muscle

Nebulin structural component of striated  
muscle sarcomere filaments

Heart

35 Connexin-43 gap junction component in  
cardiomyocytes

GATA-4 zinc finger transcription factor  
binding to FOG2 in cardiomyocytes

## Nerve

5            CXCR4            chemokine receptor for SDF-1 on neural precursors  
 Connexin-43            gap junction component on astrocytes

## Endothelium

10            CD34            haemopoietic stem cell marker. Also expressed by endothelial cells  
 CD133            cholesterol binding protein prominin 1. Lipid raft marker  
 VEGF            vascular endothelial growth factor  
 KDR            kinase insert domain receptor. A receptor for VEGF  
 15            Angiopoietin 1            angiogenesis factor. Ligand for Tie 2  
 Angiopoietin 2            angiogenesis factor. Ligand for Tek receptor for angiopoietin 1  
 Tie 2            receptor for angiopoietin 1  
 CXCR4            chemokine receptor for SDF-1. Important for vascularisation  
 20            PECAM            platelet-endothelial cell adhesion molecule  
 ICAM 2            intercellular adhesion molecule 2. Mediates leukocyte extravasation  
 VE cadherin            formation of adherens junctions  
 25            TAL-1            T cell acute leukaemia-1.  
 VWF            von Willibrand factor. Coagulation factor

## Liver

30            Alpha-1 antitrypsin  
 Cytokeratin 18  
 Nestin  
 Vimentin  
 c-met            receptor for hepatocyte growth factor  
 35            CD34            haemopoietic stem cell antigen. Also expressed on candidate liver stem cells.

## Pancreas

NGN-3 target of pdx-1 in beta cell differentiation

5

Gene expression by ASC 34 generated cells after 14 days in culture.

## Haemopoietic cell markers

10 CD133 cholesterol-binding protein prominin  
1. Lipidraft marker

PECAM platelet-endothelial cell adhesion molecule

VWF von Willibrand factor. Coagulation

15 TAL-1 T cell acute leukaemia-1. Basic helix-loop-helix protein

CXCR4 chemokine receptor for SDF-1. Important for stem cell homing and engraftment

Angiopoietin 1 ligand for Tie 2. Maintains

20 haemopoietic stem cell quiescence

## Skeletal muscle markers

25 Nebulin giant cytoskeletal protein. Structural component of striated muscle sarcomere filaments

## Heart

30 Troponin 1subunit of troponin complex

Nebulin giant cytoskeletal protein

## Nerve

35 CXCR4 chemokine receptor for SDF-1 on neural precursors

## Endothelium

- 33 -

	CD133	cholesterol-binding protein prominin 1. Lipid raft marker
	VEGF	vascular endothelial growth factor
5		Angiopoietin 1 angiogenesis factor. Ligand for Tie 2
		Angiopoietin 2 angiogenesis factor. Ligand for Tek
	CXCR4	chemokine receptor for SDF-1. Important for vascularisation
10	PECAM	platelet-endothelial cell adhesion molecule
	ICAM 2	intercellular adhesion molecule 2. Mediates leukocyte extravasation
	VWF	von Willibrand factor. Coagulation
15	TAL-1	T cell acute leukaemia-1. Basic helix-loop-helix protein
	Nebulin	giant cytoskeletal protein

#### Liver

20	Alpha-1 antitrypsin	protease inhibitor
	Cytokeratin 18	cytoskeletal component
	LDLR	low density lipoprotein receptor. Role in cholesterol homeostasis
25	Albumin	carrier protein for steroids, fatty acids and thyroid hormones
	HGF	hepatocyte growth factor
	HNF3-B	hepatocyte nuclear factor 3 beta. Transcription factor
30	Transferrin	iron transport
	AFP	alphafeto protein

#### Pancreas

	Pax-6	
35	Pdx-1	
	Insulin	counteracts hyperglycemia and stimulates lipogenesis

- 34 -

	IGF-1	insulin-like growth factor 1.
		Somatomedin
	HNF3-B	hepatocyte nuclear factor 3 beta.
5		Transcription factor expressed in
		glucagon-producing islet cells.
	NeuroD-1	regulates insulin gene expression
	NGN3	

10 Expression of insulin, PDX-1, Neuro D-1 and NGN3 gene expression by cells cultured in basic cytokines (GM-mix) was investigated at weekly intervals. The results show that insulin was expressed from day 7 to day 35, PDX-1 from day 7 to day 35, NeuroD-1 from day 14 to day 35 and NGN3 from day 21 to day 35. Thus, expression of genes involved in insulin production was sustained for 3-4 weeks with the most comprehensive expression occurring in cultures 3-5 weeks old. Thus in a preferred embodiment of the present invention the stem cells are able to generate progeny which express genes involved in insulin 20 production (insulin, PDX-1, Neuro D-1 and NGN3).

Example 12: ASC34 differentiation into haemopoietic cells  
Cells harvested from the cultures after 14 days were plated into standard haemopoietic colony-forming cell assays. Typically,  $\sim 10^3$  granulocyte-macrophage colonies formed, representing  $\sim 1\%$  of the total cells in the culture. Erythroid BFU-e, megakaryocytic (Mk-CFC) and multipotential (GEMM) colony-forming cells were also evident when the ASC34-derived cells were harvested and 30 grown in haemopoietic colony assays. More importantly, ASC34 give rise to bone marrow stroma-adherent stem/progenitor cells that form blast cell colonies/"cobblestone" areas when inoculated onto preformed cultured stroma and are capable of long term 35 haemopoietic cell production on prolonged in vitro incubation (5 weeks).

- 35 -

Cytospin preparations of the cells were made and stained with Romanowsky cytochemical stains. This revealed morphological evidence of granulocytic, monocyte-macrophage, mekakaryocytic and erythroid cell differentiation.

Example 13: Engraftment in animal models

Experiment 1: Intravenous or subcutaneous injection of large numbers ( $1 \times 10^6$ ) of ASC34-derived cells into nude mice did not cause any mortality or discernible morbidity.

Experiment 2: Nude mice that had been treated with a liver toxin (1g/kg Thioacetamide) received  $1 \times 10^6$  ASC34-derived cells including candidate hepatocytes by injection directly into the spleen. Nude mouse recipients of toxin only served as controls. All of the control mice died by day 7 whilst all of the recipients of cells survived, irrespective of whether or not they had been treated with cyclosporin (CsA) (Table 5)

**Table 5: Results of transplanting ASC34-derived cells into mice with liver damage**

25

	Tx* only control n=4	Tx+cells n=6	Tx+cells+cyclosporin n=6
% mortality at day 7	100	0	0

\* liver toxin

**Experiment 3**

30 Three experimental groups were set up: group 1, TA + cells; group 2, TA + CsA + cells; group 3, TA only. Doses of CsA were administered to group 2 animals twice per

- 36 -

week. All mice in group 3 died within 2 days after treatment with TA. Animals in groups 1 and 2 survived until sacrificed for tissue sampling (days 1, 8 and 15). Liver sections from group 2 mice stained positive for 5 human cytokeratin 18, a liver-specific marker demonstrating the presence of human ASC34-derived cells. No staining was seen on sections from control animals (Figure 16).

10 **Experiment 4**

The anti-Fas antibody JO2 was used to induce an ongoing chronic form of liver failure. Each animal received 250 µg JO2/kg/week for 4 weeks and 1x10<sup>6</sup> cells intrasplenically 24 hours after the first JO2 injection. 15 CsA was given twice weekly. Of 12 animals, there were 2 procedure-related deaths after 2 days and one animal survived for 82 days. The remainder were sacrificed for examination (one on day 2, two on day 8, three on day 13 and three on day 21).

20

The analyses presented in Figures 16-20 demonstrate that human cells engrafted in the livers of the mice and produced albumin and cytokeratin 18.

25 **Example 14: Cryopreservation and storage**

Cells (recovered adherent CD34-positive fraction or their progeny generated in culture) were suspended in 30% serum/10% DMSO in cryopreservation vials and placed in an 30 alcohol freezing bath at -80°C overnight. The frozen vials were then transferred to the vapour phase of liquid nitrogen for storage. Cells were recovered from frozen by rapidly thawing the vials in a 37°C water bath, diluting the contents with medium and washing the cells. 35 Prior to processing, the leukapheresis product can be stored for 24 hours at 37°C without any deleterious effect on subsequent viability or growth in vitro (data not

- 37 -

shown). When the adherent cells were purified before cryopreservation in 10% DMSO plus 30-50% serum then thawed they retained 92±4.8% (mean±SD) viability and there was no effect on their growth in vitro (Figure 21).

5

These results have practical implications

1. *Prior to processing:* Leukapheresis product can be stored for 24 hours at 4°C before processing.  
10 Therefore, chilled leukaphereses can be transported worldwide from the collection centre to the processing centre.
2. *After purification:* ASC34 can be suspended in 10%DMSO/30-50% serum and frozen in liquid nitrogen.  
15 On thawing they retain 90-100% viability, re-adhere to tissue culture plastic and proliferate in culture like fresh cells. Thus, isolated functional ASC34 can be transported worldwide or stored long-term.
3. *After culture:* Cells cultured for 14 days have been  
20 cryopreserved, thawed and recultured. Cells cultured for 14 days can be held at ambient temperature and retain viability. Thus, cultured cells can be transported worldwide or stored long-term.

25 Example 15: Summary of differences between ASC-34 and mesenchymal stem cells (MSC)

Mesenchymal stem cells are a separate population of cells that can be derived from adult bone marrow. MSC (also  
30 called Multipotent Adult Progenitor Cells - MAPC) and ASC-34 cells (cells of the present invention) exhibit important differences that are summarised below. It should also be noted that MSC/MAPC cells do not express CD34.

35

Characteristic	Multipotent adult progenitor cell (MAPC) *	ASC-34
Known phenotype in vivo	- <sup>1</sup>	+
Prospective isolation from tissue	-	+
Known ontogeny	-	+
Homogeneity	-	+
Quantitative assay	-	+
Quiescent in vivo	?	+ <sup>2</sup>
Produce haemopoietic cells in culture	-	+

\* Ref: Javazon, Beggs and Flake. Exp Hematol 2004, 32:414.

5

<sup>1</sup> - MAPC are only found after prolonged culture. They have not been identified in fresh bone marrow samples.

<sup>2</sup> - ASC-34 cells are resistant to 5 fluorouracil

10